BioNTech SE (BNTX) Revenue & Revenue Breakdown
BioNTech SE Revenue Highlights
Latest Revenue (Y)
$3.82B
Latest Revenue (Q)
$187.60M
Main Segment (Y)
Commercial
Main Geography (Y)
UNITED STATES
BioNTech SE Revenue by Period
BioNTech SE Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.82B | -77.94% |
| 2022-12-31 | $17.31B | -8.78% |
| 2021-12-31 | $18.98B | 3834.42% |
| 2020-12-31 | $482.32M | 344.17% |
| 2019-12-31 | $108.59M | -14.88% |
| 2018-12-31 | $127.58M | 107.11% |
| 2017-12-31 | $61.60M | - |
BioNTech SE generated $3.82B in revenue during NA 2023, up -77.94% compared to the previous quarter, and up 2993.53% compared to the same period a year ago.
BioNTech SE Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $187.60M | -87.32% |
| 2023-12-31 | $1.48B | 65.20% |
| 2023-09-30 | $895.30M | 433.87% |
| 2023-06-30 | $167.70M | -86.87% |
| 2023-03-31 | $1.28B | -70.15% |
| 2022-12-31 | $4.28B | 23.61% |
| 2022-09-30 | $3.46B | 8.28% |
| 2022-06-30 | $3.20B | -49.86% |
| 2022-03-31 | $6.37B | 15.22% |
| 2021-12-31 | $5.53B | -9.11% |
| 2021-09-30 | $6.09B | 14.67% |
| 2021-06-30 | $5.31B | 159.15% |
| 2021-03-31 | $2.05B | 492.98% |
| 2020-12-31 | $345.44M | 412.08% |
| 2020-09-30 | $67.46M | 61.53% |
| 2020-06-30 | $41.76M | 50.97% |
| 2020-03-31 | $27.66M | -1.16% |
| 2019-12-31 | $27.99M | -2.35% |
| 2019-09-30 | $28.66M | 11.16% |
| 2019-06-30 | $25.79M | -1.41% |
| 2019-03-31 | $26.15M | -58.99% |
| 2018-12-31 | $63.78M | 212.69% |
| 2018-09-30 | $20.40M | - |
BioNTech SE generated $187.60M in revenue during Q1 2024, up -87.32% compared to the previous quarter, and up 4.38% compared to the same period a year ago.
BioNTech SE Revenue Breakdown
BioNTech SE Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Research And Development | $3.50M | $116.00M | $102.70M | $178.85M | - |
| Commercial | $3.82B | $17.19B | $18.87B | $303.48M | - |
| Other Sales Transactions | - | - | - | $33.00M | - |
| Collaboration Agreement | - | - | - | - | $4.23M |
| Collaboration And License Agreement | - | - | - | - | $84.43M |
| Bill And Hold Transaction | - | - | - | - | $1.06M |
BioNTech SE's latest annual revenue breakdown by segment (product or service), as of Dec 23: Commercial (99.91%), and Research And Development (0.09%).
BioNTech SE Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| UNITED STATES | $3.01B | $12.71B | $14.64B | - |
| GERMANY | $482.70M | $2.24B | $20.60M | - |
| DELAWARE | - | $3.03B | - | - |
BioNTech SE's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (86.18%), and GERMANY (13.82%).
BioNTech SE Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BNTX | BioNTech SE | $3.82B | $187.60M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| NVAX | Novavax | $983.71M | $93.86M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| DNA | Ginkgo Bioworks | $251.46M | $56.21M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| CWBR | CohBar | - | - |
| AVRO | AVROBIO | - | - |
| ELEV | Elevation Oncology | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| OCEA | Ocean Biomedical | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ENVB | Enveric Biosciences | - | - |
BNTX Revenue FAQ
What is BioNTech SE’s yearly revenue?
BioNTech SE's yearly revenue for 2023 was $3.82B, representing a decrease of -77.94% compared to 2022. The company's yearly revenue for 2022 was $17.31B, representing a decrease of -8.78% compared to 2021. BNTX's yearly revenue for 2021 was $18.98B, representing an increase of 3834.42% compared to 2020.
What is BioNTech SE’s quarterly revenue?
BioNTech SE's quarterly revenue for Q1 2024 was $187.6M, a -87.32% decrease from the previous quarter (Q4 2023), and a -85.31% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.48B, a 65.20% increase from the previous quarter (Q3 2023), and a -65.43% decrease year-over-year (Q4 2022). BNTX's quarterly revenue for Q3 2023 was $895.3M, a 433.87% increase from the previous quarter (Q2 2023), and a -74.13% decrease year-over-year (Q3 2022).
What is BioNTech SE’s revenue growth rate?
BioNTech SE's revenue growth rate for the last 3 years (2021-2023) was -79.88%, and for the last 5 years (2019-2023) was 3416.93%.
What are BioNTech SE’s revenue streams?
BioNTech SE's revenue streams in c 23 are Research And Development, and Commercial. Research And Development generated $3.5M in revenue, accounting 0.09% of the company's total revenue, down -96.98% year-over-year. Commercial generated $3.82B in revenue, accounting 99.91% of the company's total revenue, down -77.81% year-over-year.
What is BioNTech SE’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of BioNTech SE was Commercial. This segment made a revenue of $3.82B, representing 99.91% of the company's total revenue.